Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | March 13, 2020 | March 13, 2020 |
| Vaxart, Inc.VXRT · Entity 6654 | Director | October 11, 2019 | October 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date March 13, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,716 |
Reported balance
After 2020-03-13 transaction · row 1
1 source rowRow 1 · 2020-03-13 · Purchase · Acquired 2,500 · Balance 3,716 |
Vaxart, Inc.
Report date October 11, 2019 · Filed October 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2019-10-11 transaction · row 1
1 source rowRow 1 · 2019-10-11 · Purchase · Acquired 20,000 · Balance 20,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2020 Filed Mar 13, 2020 22:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 2,500 | $3.98 | $9,950.00 |
DisclosureSEC source: 0001209191-20-019038 · doc4.xml · nonDerivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,716 Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 16:19 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon stock | 20,000 | $0.38 | $7,680.00 |
DisclosureSEC source: 0001437749-19-020035 · rdgdoc.xml · nonDerivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:13 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001209191-19-037569 · doc4.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2019. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 12,700 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012099 · rdgdoc.xml · derivative · entry 2 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2029-06-11 F2 · derivative.exercise_date: The shares subject to this option shall vest on the first anniversary of the 2019 annual meeting of stockholders of the Issuer. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-19-012099 · rdgdoc.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of February 13, 2018 (the closing date of the merger between privately-held Vaxart, Inc. and Aviragen Therapeutics, Inc.). Read SEC document |
| May 24, 2019 Filed May 28, 2019 13:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 1,000 | $8.03 | $8,030.00 |
DisclosureSEC source: 0001209191-19-032871 · doc4.xml · nonDerivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.02 to $8.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001209191-18-038138 · doc4.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:36 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherRedeemable Convertible Note · Derivative | Not disclosed | $0.00 Strike: $137.85 | $16,559.00 |
DisclosureSEC source: 0001209191-18-012450 · doc4.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 120 shares Expires not disclosed F1 · derivative.exercise_price: Reflects a 1:15 reverse stock split effected on February 10, 2017. F2 · kind: Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person. F3 · derivative.exercise_date: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively. F4 · derivative.expiration_date: The Note matured on February 19, 2018. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 22:00 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | OtherRedeemable Convertible Note · Derivative | Not disclosed | $0.00 Strike: $9.19 | $8,100.00 |
DisclosureSEC source: 0001209191-17-067088 · doc4.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 58 shares Expires not disclosed F1 · kind: Reflects a redeemable convertible note of the Issuer (the "Note") that was called for redemption by the Reporting Person at a price equal to its face value. F2 · derivative.exercise_date: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note shall be redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively. F3 · derivative.expiration_date: The Note will mature on February 19, 2018. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 15:25 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001209191-17-045311 · doc4.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 15, 2017. Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:30 UTC | Vaxart, Inc. AVIR · Entity 6654 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.49 Strike: $0.49 | $9,800.00 |
DisclosureSEC source: 0001437749-17-009783 · rdgdoc.xml · derivative · entry 1 Richard John P · CIK 0001296528 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.